[{"orgOrder":0,"company":"Nihon Medi-Physics","sponsor":"Cyclotron","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"225-Ac PET","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Undisclosed","graph3":"Nihon Medi-Physics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nihon Medi-Physics \/ Cyclotron","highestDevelopmentStatusID":"1","companyTruncated":"Nihon Medi-Physics \/ Cyclotron"}]

Find Novel Oncology Drugs in Clinical Development in JAPAN

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : Ac-225, a core material used for TAT, a new therapeutic concept to attack cancer cells in body, applying a therapeutic agent in which alpha particle-emitting radionuclides that can kill cancer cells are bound to antibodies selectively accumulated in prot...

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 04, 2022

                          Lead Product(s) : 225-Ac PET

                          Therapeutic Area : Oncology

                          Highest Development Status : Undisclosed

                          Sponsor : Cyclotron

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : Under the terms of the agreement, Merck, Taiho and Astex will combine preclinical candidates and their data with knowledge and expertise from their respective research programs.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : $50.0 million

                          June 01, 2020

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Undisclosed

                          Sponsor : Merck & Co

                          Deal Size : $2,550.0 million

                          Deal Type : Collaboration

                          blank

                          03

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : Strategic research collaboration aims at to evaluating the combination of DS-1062, a TROP2 directed DXd antibody drug conjugate, and KEYTRUDA in patients with previously-treated advanced or metastatic non-small cell lung cancer without actionable genomic...

                          Product Name : DS-1062a

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : Undisclosed

                          May 29, 2020

                          Lead Product(s) : Datopotamab Deruxtecan,Pembrolizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Undisclosed

                          Sponsor : Merck & Co

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank